JAK2 and myeloproliferative disorder: In addition, we found that pSTAT5 is expressed at slightly higher levels in CD34+/CD38− MPN-SC in JAK2 V617F+ patients compared to JAK2 V617F- patients, although the difference was not statistically significant (p = 0.073) (Figure 2B).